NextGen Vaccines: Immune Assays
A key part of development for the Project NextGen vaccine trials is harmonized immune assays that will enable analysis of vaccine-generated immune responses across trials as well as meta-analysis. The purpose of this project is to partner with performers to establish multiparameter intracellular staining (ICS) assays as part of a centralized testing resource for Project NextGen vaccine trials. The goal of this project is to establish multiparameter ICS assays to identify and quantify SARS-CoV-2-specific T-cell subsets in peripheral blood mononuclear cell (PBMC) samples.
Award Details
Development and Implementation of Validated Core and Novel Advanced Assays to Evaluate SARS-CoV-2-specific T Cells in Response to Vaccination and Infection
Project Details
Member Organization: Fred Hutchinson Cancer Center
Award Date: 12/23/2024
Award Amount: $23,826,661
Project Duration: 72 months
Solicitation Number: RRPV RPP-24-04-NGVxAssays
Project Objective: Fred Hutchinson Cancer Center’s main objective of this project is to develop and implement advanced, validated assays to define SARS-CoV-2-specific T cell responses to current and novel vaccines, and to assess the impact of circulating SARS-CoV-2 variants on vaccine immunogenicity.
